CAN-2409 Receives FDA Orphan Drug Designation in Pancreatic Cancer
CAN-2409 has received orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.
Source: onclive.com
Stay updated with breaking news from Can 2409 . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CAN-2409 has received orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.
CAN-2409 has been associated with improved survival among patients with non-metastatic, borderline resectable pancreatic ductal adenocarcinoma.